

**CLINICAL MICROARRAYS ANNOUNCES \$7.5 MILLION SERIES A FINANCING  
-- Funds to develop and commercialize multiplexed protein biomarker immunoassay  
systems –**

Natick, Mass., October 21, 2004 - Clinical MicroArrays Inc., (CMA) developer of multiplexed protein biomarker immunoassay systems for use in drug development and clinical diagnostics, today announced the closing of a \$7.5 million, Series A financing. Oxford Bioscience Partners led the financing, which also included Rock Maple Ventures, Fletcher Spaght Venture Partners, and a group of individual investors led by Jean “Coco” Montagu.

“Clinical MicroArrays’ management team has a proven track record of successful development and commercialization of proprietary, innovative technologies that address real world problems in the life sciences,” said Michael Lytton, General Partner at Oxford Bioscience Partners. “As pharmaceutical companies begin to employ panels of protein biomarkers throughout the drug development process, CMA’s technology will enable clinical utility while reducing overall drug development costs.”

Roger Dowd, President and Chief Executive Officer said, “We are very excited about the financial commitment made to our overall company strategy by each of these respected strategic investors, and the value they bring to our company.” Dowd added, “This financing will allow us to ramp-up our development efforts and drive toward early product commercialization in 2005.”

In connection with the financing, Michael Lytton of Oxford and Jason Henrichs of Rock Maple were elected to the Clinical MicroArrays’s Board of Directors. Caroline Popper, M.D. also joined as an independent director, rounding out the existing board consisting of Jean Montagu (Chairman), and Mr. Dowd. Dr. Popper was previously Chief Business Officer at MDS Proteomics and prior to that VP and General Manager at BDGene, a Becton-Dickinson Company. In summarizing the new additions to the board Mr. Montagu said, “Caroline brings a wealth of industry experience in product commercialization, strategy development and business development expertise in life sciences and diagnostics and is a welcome addition to our board.”

**About Clinical MicroArrays, Inc.**

Clinical MicroArrays, based in Natick, Mass., is a privately-held company focusing on the development of a novel technology platform enabling clinical utilization of multiplexed panels of protein biomarkers in drug development and clinical diagnostics. CMA’s technology, the MultiMark Express System, consisting of proprietary protein surface chemistry, image detection and sample processing, will fully automate the usage of disease specific biomarker panels, from sample to results, providing increased performance and ease-of-implementation in clinical testing through to companion and near-patient diagnostics. For more information, go to [www.clinicalmicroarrays.com](http://www.clinicalmicroarrays.com).

**About Oxford Bioscience Partners**

Oxford Bioscience Partners (OBP) is a life science venture capital firm that provides equity financing and management assistance to start-up, early-stage, entrepreneurial-driven companies in the bioscience and healthcare industries. The General Partners of OBP currently manage venture funds with combined committed capital of more than \$800 million. The General Partners, collectively, have served on the Board of Directors of more than 50 biotechnology and healthcare companies and have assumed the position of Chairman or President for more than 20 bioscience concerns. They have extensive operating management experience in the U.S. and abroad and have played a key role in the founding of a number of successful bioscience ventures. For more information, go to [www.oxbio.com](http://www.oxbio.com).

#### **About Rock Maple Ventures**

Rock Maple Ventures, L.P. is uniquely positioned to build leading-edge companies through in-depth experience, focus on new investments and a proprietary network for business partnerships. Rock Maple Ventures has \$80 million in capital and over 30 years of real-world executive, investment and entrepreneurial experience. For more information, go to [www.rockmapleventures.com](http://www.rockmapleventures.com).

#### **About Fletcher Spaght Ventures**

Fletcher Spaght Ventures, L.P. (FSV) is a venture capital fund investing in emerging growth high technology and healthcare companies. FSV invests in companies in the areas of information technology (IT) and IT services, Internet, software, telecommunications, medical devices, healthcare informatics, biotechnology and healthcare services. For more information, go to [www.fletcherispaght.com](http://www.fletcherispaght.com).

Contacts:

Darren Lee  
V.P. Marketing & Sales  
508-647-9258  
[dlee@clinicalmicroarrays.com](mailto:dlee@clinicalmicroarrays.com)

Douglas MacDougall  
MacDougall BioCommunications, Inc.  
508-647-0209  
[dmacdougall@macbiocom.com](mailto:dmacdougall@macbiocom.com)